Oruka Therapeutics (NASDAQ:ORKA) Now Covered by Stifel Nicolaus

Stifel Nicolaus assumed coverage on shares of Oruka Therapeutics (NASDAQ:ORKA) in a report issued on Friday, Marketbeat.com reports. The brokerage set a “buy” rating and a $49.00 price target on the stock. Stifel Nicolaus’ target price would suggest a potential upside of 88.17% from the stock’s previous close.

Several other research firms have also weighed in on ORKA. Leerink Partners assumed coverage on shares of Oruka Therapeutics in a research note on Tuesday, September 17th. They set an “outperform” rating and a $44.00 price objective on the stock. Leerink Partnrs raised shares of Oruka Therapeutics to a “strong-buy” rating in a report on Tuesday, September 17th. Jefferies Financial Group started coverage on Oruka Therapeutics in a research note on Friday, September 13th. They set a “buy” rating and a $40.00 price objective on the stock. Lifesci Capital started coverage on Oruka Therapeutics in a research note on Monday, September 16th. They issued an “outperform” rating and a $41.00 target price for the company. Finally, TD Cowen initiated coverage on Oruka Therapeutics in a research report on Monday, September 16th. They set a “buy” rating on the stock. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $43.17.

Oruka Therapeutics Price Performance

Shares of Oruka Therapeutics stock opened at $26.04 on Friday. The firm has a market cap of $31.51 million, a price-to-earnings ratio of -4.34 and a beta of 0.89. Oruka Therapeutics has a 52 week low of $18.72 and a 52 week high of $53.88.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings data on Thursday, August 1st. The company reported ($25.92) EPS for the quarter. As a group, sell-side analysts forecast that Oruka Therapeutics will post -1.62 EPS for the current year.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.